Overview: The AMNOG benefit risk assessment procedure
According to the German Drug Regulatory Affairs Act (AMNOG), manufacturers of pharmaceutical drugs must prove the additional benefit of a drug when it is launched on the market. The Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) determines which proof is required for the respective drug. Subsequently, the submitted evidence is reviewed by the Institute for Quality and Efficiency in Health Care (IQWiG). This process is called AMNOG benefit assessment.
If the additional benefit could be substantiated, negotiations are held together with the Association of Statutory Health Insurance Funds (GKV-Spitzenverband) to determine the amount of reimbursement that should be allocated.
If no additional benefit could be determined according to the AMNOG benefit assessment, the amount of the market price for the drug will be limited. Alternatively, the drug is grouped with comparable drugs for which a fixed amount already applies (reimbursement ceiling). If no agreement can be reached, the final decision is taken by an impartial third party.
In our AMNOG Benefit Assessment Database you can see all the necessary information on current and completed benefit risk assessment procedures at a glance:
- Dossier of the pharmaceutical entrepreneur
- Information on the comparative therapy
- Information from IQWiG’s benefit risk assessment
- Minutes of the oral hearing
- Resolution & Reasons
- AMNOG mandatory discounts
- European Comparison Price
Source: G-BA (Gemeinsamer Bundesausschuss)
This database can be accessed after purchasing the subscription package ‘Drug Pricing’ or ‘Premium’
Product tour: AMNOG Database – Early Benefit Assessment (IQWIG / G-BA)
What functions does the AMNOG Benefit Assessment Database include in detail?
This database compiles information on the benefit assessment of medicinal products in accordance with the Act on the Reform of the Market for Medicinal Products (AMNOG). Resolutions are partly also translated into English.
FULL-TEXT SEARCH IN AMNOG
- Simply search through the resolutions of the Federal Joint Committee (G-BA), including the reasons and the IQWiG’s concise benefit assessment
- The direct connection of the documents to the German Drug Pricing Database enables a structured database search via the pharmaceutical central number (PZN) and other criteria
ACCESS TO INFORMATION ON THE OFFICIAL GBA PROCEDURES WEBSITE:
- Profile, deadlines, title and commentary of the procedures
- Documents of the decision-making process
INFORMATION RESULTING FROM THE GBA DECISIONS
- area of application
- additional benefit
- relevant and purposeful comparative therapy
- yearly therapy costs
INFORMATION OF THE MAIN REASONS OF THE GBA:
- Reason & course of the limitation of the period of validity
- Duration of the consultation
INFORMATION FROM THE VERBATIM RECORDS OF THE GBA:
- Duration of the hearing
INFORMATION FROM THE DATA OF THE GBA:
- Comparison: pharmaceutical companies vs. IQWiG vs. G-BA
- full text search in the summary of the GBA benefit risk assessment
- Indication expansions
- Look up inventory market
- Grouping in fixed amount group
- Closed, exempted and open procedures
Save your AMNOG searches in the German Drug Pricing Database:
- Easily create and classify your own search queries
- Search directly for keywords within the ABDA Database
- Export of the results to Excel
- Display of prescription requirements
- Integration of registration documents and package inserts
- Daily news from the federal institutes
- Price histories of AMNOG drugs on pharmacy central number basis via our PharMonitor
- Individual contents: The AMNOG Benefit Assessment Database can be expanded to include access to other databases.
For example, monitoring, price history or discount agreements with health insurance companies
- Price history per PZN
What are the current challenges of the AMNOG benefit risk accessment procedure?
Over the past years, the AMNOG procedure has proven to be a reliable means of fairly pricing drugs with added value on the market. Nevertheless, the AMNOG procedure is still facing challenges.
- The requirements of the regulatory authorities must always be aligned with the design and implementation requirements of the GBA at an early stage – both nationally and at the European level
- There must be no excessive price pressure on pharmaceutical companies, which would prevent or hinder the market launch of important drugs and thus innovation
- The legally binding prescription of medicines with reimbursement must be given by the doctors. The final selection of the appropriate medication should be based purely on the needs of the patient and not on AMNOG
These databases could also be interesting for you
The new Falsified Medicines Directive 2019 - which medicines are affected? As of 9. February 2019, the Falsified Medicines Directive (2011/62/EU), which was adopted in 2011, has officially come into force. What does this mean for the affected players such as...
Estimating the final price of a prescription-only product At a glance: Pricing for pharmaceuticals in Germany Supply and demand determine the price, at least considering most branches of a free market economy. This basic principle also applies to non-prescription...
Drug Pricing Tool German Medicinal Products - ABDA-Artikelstamm (Taxe)The Drug Pricing Tool German Medicinal Products - ABDA-Artikelstamm (Taxe) includes all economic data for all drugs sold in pharmacies in Germany. Pressed to make pricing decisions? Need to...